drugset / Trial / NCT00868231

Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00868231

Phase 2 Completed 30 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe COPD patients.

Timeline

Start
2009-03
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 400 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled